Financial Performance & Growth - RadNet's Q3 2025 revenue increased by 13.4% compared to Q3 2024, achieving record quarterly revenue[22] - The company's adjusted EBITDA margin increased by 26 basis points to 16.2%[20] - RadNet has a strong liquidity position with $804.7 million in cash balance and a net debt to adjusted EBITDA leverage ratio of approximately 1.0x[22] - The company anticipates a revenue CAGR of +11% to +13% and a Digital Health revenue CAGR of ~30% from 2025 to 2028[788] Procedural Volume Growth - MRI procedural volume grew by 14.8% in aggregate and 11.5% on a same-center basis[21] - CT procedural volume increased by 9.4% in aggregate and 6.7% on a same-center basis[21] - PET/CT procedural volume experienced a significant increase of 21.1% in aggregate and 14.9% on a same-center basis[21] Technology & Innovation - Deep Learning Reconstruction (DLR) allows for 50-75% faster MRIs while improving image quality[43] - RadNet performs over 2 million mammograms a year, representing 5% of all mammograms in the US[283] - AI-assisted reads found clinically significant prostate cancer in 24% of men when MRI was deemed negative by the radiologist[343] Market Trends & Opportunities - The national imaging market is estimated at $100 billion in 2025[568] - The company's joint venture revenue is projected to reach ~$800 million in 2025, reflecting a CAGR of 19.1% from 2022 to 2025[607] - The company has seen ~18x increase in Cardiac CTA volume from Jan 2020 to October 2025[506]